HealthEquity price target raised to $92 from $90 at RBC Capital

RBC Capital raised the firm’s price target on HealthEquity to $92 from $90 and keeps an Outperform rating on the shares. The company’s Q4 results exceeded the upper ends of its pre-announced ranges, while over the longer term, HealthEquity remains confident in its previously-communicated plans to double adjusted EPS over the next three years via a combination of revenue growth and cost efficiency initiatives, the analyst tells investors in a research note.